Clinical trials: Hypokinesia
Hypoactive Sexual Desire Disorder, Female Sexual Dysfunction
BP101 for Adults With Female Sexual Dysfunction
This study is to confirm efficacy and safety of study drug BP101 in female patients with with decrease or loss of sexual desire, which is equal to acquired generalized hypoactive sexual desire disorder (HSDD).
- Conditions
- Hypoactive Sexual Desire Disorder, Female Sexual Dysfunction, Sexual Desire Disorder
- Trial name
- NCT03463707
- Testing
- BP101
- Where
- 20 sites in Russia
- Volunteers
- 205 people
- Sponsor
- Ivix LLX
Hypoactive Sexual Desire Disorder
Study of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido
This study is designed to evaluate efficacy and safety of a testosterone patch as treatment for low libido in naturally menopausal women who are taking estrogen or estrogen/progestin therapy.
- Trial name
- NCT00338312
- Testing
- Testosterone Transdermal System
- Where
- United States
- Volunteers
- 610 people
- Sponsor
- Warner Chilcott
Hypoactive Sexual Desire Disorder
A Pharmacokinetic (PK) Study to Compare the Absorption of Two Formulations of Transdermal Testosterone Spray and Intrinsa®
The purpose of this study is to determine if the absorption of the testosterone spray is the same as the Intrinsa® Patch.
- Trial name
- NCT01096329
- Testing
- Testosterone Spray 5% and 1%, Intrinsa® Patch and Testosterone Spray 5%, Intrinsa® Patch and Testosterone Spray 1%
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Parkinson's Disease
Bradykinesia Subscale Administered Alone Versus Regular Administration: Psychometric Properties
The purpose of this study is to examine whether scores on questionnaires that rate how much Parkinson's Disease (PD) has slowed movements of the body differ when the order of the questions are changed.
- Trial name
- Bravura (NCT00932581)
- Testing
- Bradykinesia UPDRS Motor Full Examination, Bradykinesia subscale of UPDRS Motor Examination
- Volunteers
- 110 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Sexual Dysfunctions, Psychological
Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder
The object of this trial is to assess the safety and efficacy of a 24 week course of flibanserin for the treatment of hypoactive sexual desire disorder in premenopausal women.
- Trial name
- NCT00996164
- Testing
- Flibanserin
- Where
- 75 sites in United States
- Volunteers
- 1,090 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Parkinson's Disease
Kinesia HomeView - Home Diary Comparison
The objective is to compare the sensitivity and test-retest reliability of Kinesia HomeView to electronic and hand-written diaries for tracking medication state in the home.
- Trial name
- NCT01920425
- Testing
- Kinesia HomeView, Hand-written diary
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Great Lakes NeuroTechnologies Inc.
Parkinson's Disease, Essential Tremor
Movement Disorder Quantification Algorithm Development
The purpose of this study is to collect kinematic motion data from subjects with movement disorders such as Parkinson's disease (PD) and essential tremor (ET) to develop and validate algorithms for quantifying motor symptoms such…
- Trial name
- NCT01534650
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Great Lakes NeuroTechnologies Inc.
Parkinson's Disease
BradyXplore Phase II: Bradykinesia Feature Extraction System
Study objectives are to improve motion sensor algorithms for measuring bradykinesia in the clinic and the home, evaluate test-retest reliability of motion sensor algorithms for measuring bradykinesia compared to clinician raters…
- Trial name
- NCT02358876
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Great Lakes NeuroTechnologies Inc.
Sexual Dysfunctions, Psychological
Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
This trial examines the way flibanserin is metabolized in postmenopausal women with Hypoactive Sexual Desire Disorder.
- Trial name
- NCT01188603
- Testing
- flibanserin 100 mg dose every evening
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Sexual Dysfunction, Psychological
Zestra in Women With Mixed Sexual Dysfunction
The objective of this study is to evaluate the clinical efficacy and safety of Zestra(TM) in women with acquired mixed desire/interest/arousal/orgasm disorders under conditions of home usage.
- Trial name
- NCT00118495
- Testing
- Non-prescription Zestra(TM): patented formulation
- Where
- 13 sites in United States
- Volunteers
- 200 people
- Sponsor
- QualiLife Pharmaceuticals
Female Sexual Arousal Disorder, Hypoactive Sexual Desire Disorder
Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder
This trial is designed to evaluate the efficacy and safety of 3 fixed dose levels of bremelanotide, administered subcutaneously on an as-needed basis under conditions of home use, for the treatment of female sexual arousal…
- Trial name
- NCT01382719
- Testing
- bremelanotide
- Where
- 68 sites in United States, Canada
- Volunteers
- 612 people
- Sponsor
- Palatin Technologies, Inc
Sexual Dysfunctions, Psychological
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women
The objective of this trial is to assess the safety and efficacy of 24-week course of flibanserin for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in naturally postmenopausal women.
- Trial name
- NCT00996372
- Testing
- flibanserin
- Where
- 75 sites in United States
- Volunteers
- 949 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Hypoactive Sexual Desire Disorder
A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)
The purpose of this study is to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women with Hypoactive Sexual Desire Disorder(with or without Decreased Arousal).
- Trial name
- NCT04943068
- Testing
- Bremelanotide
- Where
- South Korea
- Volunteers
- 193 people
- Sponsor
- Kwang Dong Pharmaceutical co., ltd.
Hypoactive Sexual Desire Disorder
1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an optional Open-label Extension to evaluate the efficacy of bremelanotide (BMT), administered subcutaneously (SC) on an as needed basis for the…
- Trial name
- HSDD (NCT02333071)
- Testing
- Bremelanotide
- Where
- 91 sites in United States, Canada
- Volunteers
- 723 people
- Sponsor
- Palatin Technologies, Inc
Bradykinesia
Evaluate Umbilical Cord-derived Allogeneic Mesenchymal Stem Cells for the Treatment of Bradykinesia
Investigate the safety and tolerability of umbilical cord-derived allogeneic mesenchymal stem cells to treat patients with Bradykinesia.
- Trial name
- NCT04385056
- Testing
- MSCTC-0010
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- IMAC Holdings, Inc.
Hypoactive Sexual Desire Disorder
Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women
This study is a randomized, double-blind, placebo-controlled, adaptive design, multi-center study of the long-term cardiovascular and breast safety of LibiGel in the treatment of HSDD in postmenopausal women with at least two…
- Trial name
- BLOOM (NCT00612742)
- Testing
- testosterone gel
- Where
- 149 sites in United States, Canada
- Volunteers
- 3,656 people
- Sponsor
- BioSante Pharmaceuticals
Bladder Outlet Obstruction, Multiple Sclerosis
GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology
Male self catherterisng observational study.
- Conditions
- Bladder Outlet Obstruction, Multiple Sclerosis, Cauda Equina Syndrome, Enlarged Prostate With Lower Urinary Tract Symptoms
- Trial name
- NCT05470751
- Testing
- Intermittent self-catheterisation
- Where
- 16 sites in United States, France and 1 more
- Volunteers
- 72 people
- Sponsor
- ConvaTec Inc.
Detrusor Underactivity, Overactive Bladder
Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder.
The purpose of this study is to evaluate the efficacy and safety of TAC-302 in detrusor underactivity patients with overactive bladder.
- Trial name
- NCT03175029
- Testing
- TAC-302
- Where
- Japan
- Volunteers
- 195 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Hypoactive Sexual Desire Disorder
Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women
This study is designed to evaluate the endometrial safety of a testosterone patch as treatment for low libido in naturally postmenopausal women.
- Trial name
- NCT00467259
- Testing
- Testosterone Transdermal System
- Where
- 115 sites in United States
- Volunteers
- 1,271 people
- Sponsor
- Warner Chilcott
Hypoactive Sexual Desire Disorder
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)
The objective of this study is to evaluate the persistence of benefit of LibiGel (testosterone gel) 300 mcg/day compared to placebo gel in a 12 week post-treatment period of Hypoactive Sexual Desire Disorder (HSDD) in surgically…
- Trial name
- NCT01235754
- Testing
- transdermal testosterone gel 1%
- Where
- 102 sites in United States, Canada
- Volunteers
- 626 people
- Sponsor
- BioSante Pharmaceuticals